Jianyi Yin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jianyi Yin has a total of 148 co-authors. Here are the top co-authors by number of shared publications:
- Mark Donowitz
Johns Hopkins University School of Medicine
6 shared publications - David I. Fudman
Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center , Dallas, TX
4 shared publications Jian Wang
Department of Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, P. R. China
4 shared publicationsRafiquel Sarker
4 shared publicationsDanhua Yao
Department of Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, P. R. China
3 shared publications- Ezra Burstein
Department of Internal Medicine, UT Southwestern Medical Center, Dallas, USA
3 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Oxford University Press (OUP) in Crohn’s & Colitis 360
- Vol. 8 (4)
Risk factors of short-term colectomy following Janus kinase inhibitor therapy in acute severe ulcerative colitis: a systematic review and meta-analysis of individual-level data from real-world studies
Background: Emerging evidence supports the use of Janus kinase inhibitors (JAKi) in acute severe ulcerative colitis (ASUC). However, risk factors associated with non-response and the need for short-term colectomy in ASUC patients treated with JAKi remain poorly understood. Methods: We conducted a systematic review and individual-level data meta-analysis of real-world studies evaluating tofacitinib or upadacitinib for the treatment of ASUC. The primary and secondary outcomes were colectomy within 30 days and 12 weeks, respectively. Generalized linear mixed-effects models were used for univariable and multivariable analyses to estimate odds ratios (ORs). A stratified Cox proportional hazards model was used to assess colectomy-free survival. Results: Twenty-three studies with 145 patients were included (69.0% treated with tofacitinib, 31.0% with upadacitinib). The overall colectomy rate was 13.1% within 30 days and 20.5% within 12 weeks. In univariable analyses, prior exposure to anti-tumor necrosis factor (TNF) therapy before ASUC hospitalization was statistically significantly associated with lower odds of colectomy within 30 days (OR 0.44, P = .006) and 12 weeks (OR 0.51, P = .008). Prior anti-TNF exposure remained significantly associated with lower odds of colectomy in multiple multivariable analyses. No other clinical or laboratory variables were significantly associated with primary/secondary outcomes. Conclusions: Prior anti-TNF exposure before hospitalization is associated with lower short-term colectomy rates in ASUC patients treated with JAKi. Our findings highlight the need for future studies to optimize the position of JAKi in the ASUC management algorithm and to identify novel predictive biomarkers to advance precision medicine strategies.
- 5 October 2026
- Published by Oxford University Press (OUP) in Crohn’s & Colitis 360
- Vol. 8 (4)
Open AccessRisk factors of short-term colectomy following Janus kinase inhibitor therapy in acute severe ulcerative colitis: a systematic review and meta-analysis of individual-level data from real-world studies
Background: Emerging evidence supports the use of Janus kinase inhibitors (JAKi) in acute severe ulcerative colitis (ASUC). However, risk factors associated with non-response and the need for short-term colectomy in ASUC patients treated with JAKi remain poorly understood. Methods: We conducted a systematic review and individual-level data meta-analysis of real-world studies evaluating tofacitinib or upadacitinib for the treatment of ASUC. The primary and secondary outcomes were colectomy within 30 days and 12 weeks, respectively. Generalized linear mixed-effects models were used for univariable and multivariable analyses to estimate odds ratios (ORs). A stratified Cox proportional hazards model was used to assess colectomy-free survival. Results: Twenty-three studies with 145 patients were included (69.0% treated with tofacitinib, 31.0% with upadacitinib). The overall colectomy rate was 13.1% within 30 days and 20.5% within 12 weeks. In univariable analyses, prior exposure to anti-tumor necrosis factor (TNF) therapy before ASUC hospitalization was statistically significantly associated with lower odds of colectomy within 30 days (OR 0.44, P = .006) and 12 weeks (OR 0.51, P = .008). Prior anti-TNF exposure remained significantly associated with lower odds of colectomy in multiple multivariable analyses. No other clinical or laboratory variables were significantly associated with primary/secondary outcomes. Conclusions: Prior anti-TNF exposure before hospitalization is associated with lower short-term colectomy rates in ASUC patients treated with JAKi. Our findings highlight the need for future studies to optimize the position of JAKi in the ASUC management algorithm and to identify novel predictive biomarkers to advance precision medicine strategies.
- Open Access
- 5 October 2026
- Published by Oxford University Press (OUP) in Crohn’s & Colitis 360
- Vol. 8 (4)
Real-world success of de-escalating upadacitinib induction dosing in ulcerative colitis is predicted by steroid-free clinical and biochemical remission, not induction duration
Background: Data guiding upadacitinib dose de-escalation in ulcerative colitis (UC) are limited. We evaluated factors associated with UC-related complications (UCRC) after upadacitinib was reduced from 45 mg daily. Methods: This retrospective study included adults with UC at a tertiary center who underwent upadacitinib de-escalation (4/2022-11/2025). The primary outcome was a 12-month composite of UCRC (upadacitinib re-escalation or discontinuation, new systemic steroids, new advanced therapy, hospitalization, or colectomy). Predictors of UCRC after de-escalation were assessed using Cox proportional hazards modeling, including steroid-free clinical remission (SFCR), defined as a stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0 without systemic steroid use, and biochemical remission, defined as a fecal calprotectin (FC) < 150 μg/g or a C-reactive protein (CRP) < 5 mg/L when FC was unavailable. Optimal CRP and FC cut points were identified via ROC curves. Results: Among 70 patients, 25 (35.7%) experienced UCRC (median follow-up 56 weeks). Induction duration, prior advanced therapy exposure, and endoscopic severity did not differ significantly between those with and without UCRC. Patients without UCRC were more likely to have achieved SFCR (51.1% vs 20.0%, P=.01) and biochemical remission (53.3% vs 28.0%, P=.04) prior to de-escalation, with lower median CRP (0.8 vs 1.5 mg/L, P=.04) and FC (79.5 vs 208.0 μg/g, P=.03). In multivariable analysis, achieving SFCR (aHR 0.33, 95% CI, 0.12-0.91) and biochemical remission (aHR 0.34, 95% CI, 0.13-0.85) independently predicted lower UCRC risk, and achieving both conferred additional UCAE-free survival benefit. Optimal cut points predicting UCRC were CRP > 12.7 mg/L (sensitivity 40%, specificity 93%) and FC > 58.7 μg/g (sensitivity 100%, specificity 47%). Conclusions: SFCR and biochemical remission prior to upadacitinib de-escalation, but not induction duration, predict lower UCRC risk. Upadacitinib de-escalation should be guided by response assessment rather than a predetermined induction duration.
- 5 October 2026
- Published by Oxford University Press (OUP) in Crohn’s & Colitis 360
- Vol. 8 (4)
Open AccessReal-world success of de-escalating upadacitinib induction dosing in ulcerative colitis is predicted by steroid-free clinical and biochemical remission, not induction duration
Background: Data guiding upadacitinib dose de-escalation in ulcerative colitis (UC) are limited. We evaluated factors associated with UC-related complications (UCRC) after upadacitinib was reduced from 45 mg daily. Methods: This retrospective study included adults with UC at a tertiary center who underwent upadacitinib de-escalation (4/2022-11/2025). The primary outcome was a 12-month composite of UCRC (upadacitinib re-escalation or discontinuation, new systemic steroids, new advanced therapy, hospitalization, or colectomy). Predictors of UCRC after de-escalation were assessed using Cox proportional hazards modeling, including steroid-free clinical remission (SFCR), defined as a stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0 without systemic steroid use, and biochemical remission, defined as a fecal calprotectin (FC) < 150 μg/g or a C-reactive protein (CRP) < 5 mg/L when FC was unavailable. Optimal CRP and FC cut points were identified via ROC curves. Results: Among 70 patients, 25 (35.7%) experienced UCRC (median follow-up 56 weeks). Induction duration, prior advanced therapy exposure, and endoscopic severity did not differ significantly between those with and without UCRC. Patients without UCRC were more likely to have achieved SFCR (51.1% vs 20.0%, P=.01) and biochemical remission (53.3% vs 28.0%, P=.04) prior to de-escalation, with lower median CRP (0.8 vs 1.5 mg/L, P=.04) and FC (79.5 vs 208.0 μg/g, P=.03). In multivariable analysis, achieving SFCR (aHR 0.33, 95% CI, 0.12-0.91) and biochemical remission (aHR 0.34, 95% CI, 0.13-0.85) independently predicted lower UCRC risk, and achieving both conferred additional UCAE-free survival benefit. Optimal cut points predicting UCRC were CRP > 12.7 mg/L (sensitivity 40%, specificity 93%) and FC > 58.7 μg/g (sensitivity 100%, specificity 47%). Conclusions: SFCR and biochemical remission prior to upadacitinib de-escalation, but not induction duration, predict lower UCRC risk. Upadacitinib de-escalation should be guided by response assessment rather than a predetermined induction duration.
- Open Access
B3GNT7 regulates mucin glycosylation and protects against colitis and infection
Mucus covers and protects colonic epithelial cells. Mucus is mainly composed of heavily O-glycosylated proteins called mucins, and disruption of normal mucin glycosylation occurs in ulcerative colitis (UC). Mucin-2 (MUC2) is the major colonic mucin, and MUC2 O-glycans are often extended with sulfated polyLacNAc, also known as keratan sulfate (KS). The GlcNAc residues in KS are added by B3GNT family members. B3GNT7 is highly expressed in the colon, and B3GNT7 expression is dramatically reduced in UC. However, the function of B3GNT7 in colonic physiology is unexplored. Here we show that B3gnt7 is a key player in colonic physiology through its function in controlling the structure of mucus glycans. We found that B3GNT7 prefers to extend a sulfated acceptor substrate and is required for production of polyLacNAc-modified mucus in a human goblet cell model. In vivo, B3GNT7 regulates Muc2, Muc13, and Muc17 O-glycosylation. Intestinal B3GNT7 deficiency increases susceptibility to colitis and enteric infection in mice, showing that B3GNT7-dependent glycosylation confers protective properties to colonic mucus. Taken together, these results demonstrate that B3GNT7 has a function distinct from other B3GNT family members and is critical for maintaining colonic homeostasis.
Open AccessB3GNT7 regulates mucin glycosylation and protects against colitis and infection
Mucus covers and protects colonic epithelial cells. Mucus is mainly composed of heavily O-glycosylated proteins called mucins, and disruption of normal mucin glycosylation occurs in ulcerative colitis (UC). Mucin-2 (MUC2) is the major colonic mucin, and MUC2 O-glycans are often extended with sulfated polyLacNAc, also known as keratan sulfate (KS). The GlcNAc residues in KS are added by B3GNT family members. B3GNT7 is highly expressed in the colon, and B3GNT7 expression is dramatically reduced in UC. However, the function of B3GNT7 in colonic physiology is unexplored. Here we show that B3gnt7 is a key player in colonic physiology through its function in controlling the structure of mucus glycans. We found that B3GNT7 prefers to extend a sulfated acceptor substrate and is required for production of polyLacNAc-modified mucus in a human goblet cell model. In vivo, B3GNT7 regulates Muc2, Muc13, and Muc17 O-glycosylation. Intestinal B3GNT7 deficiency increases susceptibility to colitis and enteric infection in mice, showing that B3GNT7-dependent glycosylation confers protective properties to colonic mucus. Taken together, these results demonstrate that B3GNT7 has a function distinct from other B3GNT family members and is critical for maintaining colonic homeostasis.
- Open Access
The CCC complex directs phagosomal maturation and bactericidal activity in macrophages through PI(3)P regulation
Phagocytosis, the process by which immune cells ingest and eliminate invading pathogens, is essential for host defense. During this process, phagosomes mature through the recruitment of several effector proteins, such as V-ATPases, proteases, and other enzymes, to effectively degrade the pathogen they contain. These maturation events are thought to be regulated by phosphoinositide transitions, which facilitate phagosome-lysosome fusion. The evolutionarily conserved COMMD/CCDC22/CCDC93 (CCC) complex regulates endosomal recycling and has been identified on phagosomes. Nevertheless, its role in phagosome maturation has not been previously demonstrated. Here, we show that the CCC complex is essential for efficient bacterial clearance by bone marrow-derived macrophages (BMDMs) and the temporal remodeling of phagosomal protein composition. We further reveal that the CCC complex regulates phagosome-lysosome fusion and identify excessive phosphatidylinositol-3-phosphate (PI(3)P) accumulation on phagosome membranes in CCC deficient states, leading to impaired phagosome function. Collectively, our findings uncover a previously unknown role for the CCC complex in innate immune defense.
Open AccessThe CCC complex directs phagosomal maturation and bactericidal activity in macrophages through PI(3)P regulation
Phagocytosis, the process by which immune cells ingest and eliminate invading pathogens, is essential for host defense. During this process, phagosomes mature through the recruitment of several effector proteins, such as V-ATPases, proteases, and other enzymes, to effectively degrade the pathogen they contain. These maturation events are thought to be regulated by phosphoinositide transitions, which facilitate phagosome-lysosome fusion. The evolutionarily conserved COMMD/CCDC22/CCDC93 (CCC) complex regulates endosomal recycling and has been identified on phagosomes. Nevertheless, its role in phagosome maturation has not been previously demonstrated. Here, we show that the CCC complex is essential for efficient bacterial clearance by bone marrow-derived macrophages (BMDMs) and the temporal remodeling of phagosomal protein composition. We further reveal that the CCC complex regulates phagosome-lysosome fusion and identify excessive phosphatidylinositol-3-phosphate (PI(3)P) accumulation on phagosome membranes in CCC deficient states, leading to impaired phagosome function. Collectively, our findings uncover a previously unknown role for the CCC complex in innate immune defense.
- 20 May 2024
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 30 (10) , 1914-1916
Short-Term Use of Upadacitinib in Combination With Biologic Therapy for Inducing Clinical Remission in Patients With Active Inflammatory Bowel Disease
Lay Summary: We report that upadacitinib intended for short-term use in combination with biologic therapy appeared to be effective in inducing steroid-free clinical remission in patients with active inflammatory bowel disease, but a substantial proportion of patients required extended use.
- 20 May 2024
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 30 (10) , 1914-1916
Short-Term Use of Upadacitinib in Combination With Biologic Therapy for Inducing Clinical Remission in Patients With Active Inflammatory Bowel Disease
Lay Summary: We report that upadacitinib intended for short-term use in combination with biologic therapy appeared to be effective in inducing steroid-free clinical remission in patients with active inflammatory bowel disease, but a substantial proportion of patients required extended use.
- Open Access
- 22 December 2023
- Published by Oxford University Press (OUP) in Gastroenterology Report
- Vol. 12, goae013
Isolated gastrointestinal histoplasmosis with a negative urine antigen test mimicking ulcerative colitis flare: a case report
Histoplasmosis is a mycotic infection caused by Histoplasma capsulatum. The usual clinical presentation is pulmonary disease. Disseminated disease can occur and involve multiple organs [ 1]. Gastrointestinal (GI) involvement can be seen in 70% of autopsy cases, but only 3%–12% are symptomatic [ 1]. Moreover, isolated GI histoplasmosis without accompanying pulmonary symptoms is exceedingly rare. Recognizing this rare entity can be difficult, especially in patients with pre-existing GI disorders such as inflammatory bowel disease (IBD).
- 22 December 2023
- Published by Oxford University Press (OUP) in Gastroenterology Report
- Vol. 12, goae013
Open AccessIsolated gastrointestinal histoplasmosis with a negative urine antigen test mimicking ulcerative colitis flare: a case report
Histoplasmosis is a mycotic infection caused by Histoplasma capsulatum. The usual clinical presentation is pulmonary disease. Disseminated disease can occur and involve multiple organs [ 1]. Gastrointestinal (GI) involvement can be seen in 70% of autopsy cases, but only 3%–12% are symptomatic [ 1]. Moreover, isolated GI histoplasmosis without accompanying pulmonary symptoms is exceedingly rare. Recognizing this rare entity can be difficult, especially in patients with pre-existing GI disorders such as inflammatory bowel disease (IBD).
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Tu1577: SORTING NEXIN-27 REGULATES THE ROUTE OF APICAL MEMBRANE TRAFFICKING OF DRA BY PREVENTING RETROGRADE TRAFFICKING IN INTETNAL EPITHELIAL CELLS
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Tu1577: SORTING NEXIN-27 REGULATES THE ROUTE OF APICAL MEMBRANE TRAFFICKING OF DRA BY PREVENTING RETROGRADE TRAFFICKING IN INTETNAL EPITHELIAL CELLS
- 1 February 2022
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 20 (3) , 260-269
Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma
- 1 February 2022
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 20 (3) , 260-269
Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma
- Open Access
Obesity phenotypes are preserved in intestinal stem cell enteroids from morbidly obese patients
Obesity and obesity-related comorbidities are significant health care challenges. Bariatric surgery (BS) is the most effective therapy for treating obesity and type 2 diabetes. A barrier in the development of therapeutic alternatives is incomplete mechanistic understanding of the benefits of BS and the lack of human intestinal models that recapitulate the pathophysiology of obesity. Using adult intestinal stem cell-derived enteroid cultures established from healthy lean subjects and morbidly obese patients, including post-BS cases, four phenotypes correlating patient BMI and intestinal glucose absorption were identified suggesting that enteroids retain patient phenotype heterogeneity associated with healthy and diseased state. In a sub-population of obese patients, increased dietary glucose absorption and gluconeogenesis was due to significantly higher expression of intestinal carbohydrate transporters (SGLT1, GLUT2 and GLUT5) and gluconeogenic enzymes (PEPCK1 and G6Pase) compared to enteroids from lean subjects that demonstrated low glucose absorption and lacked gluconeogenesis. Enteroids established from successful BS cases exhibited low glucose absorption similar to that observed in lean subjects. These data show that human enteroids preserve the patient phenotype in long-term cultures and represent a reliable preclinical model to study the heterogeneity of the obesity mechanisms, which is necessary to determine the efficacy of therapeutic interventions.
Open AccessObesity phenotypes are preserved in intestinal stem cell enteroids from morbidly obese patients
Obesity and obesity-related comorbidities are significant health care challenges. Bariatric surgery (BS) is the most effective therapy for treating obesity and type 2 diabetes. A barrier in the development of therapeutic alternatives is incomplete mechanistic understanding of the benefits of BS and the lack of human intestinal models that recapitulate the pathophysiology of obesity. Using adult intestinal stem cell-derived enteroid cultures established from healthy lean subjects and morbidly obese patients, including post-BS cases, four phenotypes correlating patient BMI and intestinal glucose absorption were identified suggesting that enteroids retain patient phenotype heterogeneity associated with healthy and diseased state. In a sub-population of obese patients, increased dietary glucose absorption and gluconeogenesis was due to significantly higher expression of intestinal carbohydrate transporters (SGLT1, GLUT2 and GLUT5) and gluconeogenic enzymes (PEPCK1 and G6Pase) compared to enteroids from lean subjects that demonstrated low glucose absorption and lacked gluconeogenesis. Enteroids established from successful BS cases exhibited low glucose absorption similar to that observed in lean subjects. These data show that human enteroids preserve the patient phenotype in long-term cultures and represent a reliable preclinical model to study the heterogeneity of the obesity mechanisms, which is necessary to determine the efficacy of therapeutic interventions.
- Open Access
- 14 November 2019
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 6 (12) , ofz492
Oral Vancomycin May Be Associated With Earlier Symptom Resolution Than Metronidazole for Hospitalized Children With Nonsevere Clostridioides difficile Infections
National guidelines recommend oral vancomycin over oral metronidazole as first-line treatment for nonsevere Clostridioides difficile infection (CDI) in adults. Guidelines recommend metronidazole for children with nonsevere CDI, emphasizing that comparative effectiveness studies comparing the relative efficacy of vancomycin and metronidazole are lacking in children. We conducted an observational study of hospitalized children with nonsevere CDI treated with metronidazole versus vancomycin using an inverse probability of treatment-weighted propensity-score analysis. All of the following criteria had to be present for children with positive CDI testing for study eligibility: (1) ≥3 new-onset unformed stools within a 24-hour period; (2) 2–17 years of age; (3) hospitalization for ≥48 hours for CDI; (4) no laxative use ≤48 hours; (5) no alternate etiology for diarrhea; (6) no previous episode of CDI ≤3 months; (7) no concurrent non-CDI–targeted antibiotic therapy, and (8) no severe or fulminant CDI. One hundred ninety-two patients met eligibility criteria; 141 (73.4%) received oral metronidazole and 51 (26.6%) children received oral vancomycin. Baseline characteristics were similar between the 2 groups in the weighted cohort. Of 141 patients, 101 (71.7%) children receiving metronidazole had clinical improvement by day 5, whereas 44 of 51 (86.3%) cases resolved with vancomycin (odds ratio, 0.40; 95% confidence interval, 0.17–0.97; P = .04). The odds of CDI recurrence within 12 weeks were similar between the groups. Our study suggests that children with nonsevere CDI have earlier resolution of clinical symptoms when prescribed vancomycin compared with metronidazole. Large interventional studies are necessary to evaluate the reproducibility of our findings.
- 14 November 2019
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 6 (12) , ofz492
Open AccessOral Vancomycin May Be Associated With Earlier Symptom Resolution Than Metronidazole for Hospitalized Children With Nonsevere Clostridioides difficile Infections
National guidelines recommend oral vancomycin over oral metronidazole as first-line treatment for nonsevere Clostridioides difficile infection (CDI) in adults. Guidelines recommend metronidazole for children with nonsevere CDI, emphasizing that comparative effectiveness studies comparing the relative efficacy of vancomycin and metronidazole are lacking in children. We conducted an observational study of hospitalized children with nonsevere CDI treated with metronidazole versus vancomycin using an inverse probability of treatment-weighted propensity-score analysis. All of the following criteria had to be present for children with positive CDI testing for study eligibility: (1) ≥3 new-onset unformed stools within a 24-hour period; (2) 2–17 years of age; (3) hospitalization for ≥48 hours for CDI; (4) no laxative use ≤48 hours; (5) no alternate etiology for diarrhea; (6) no previous episode of CDI ≤3 months; (7) no concurrent non-CDI–targeted antibiotic therapy, and (8) no severe or fulminant CDI. One hundred ninety-two patients met eligibility criteria; 141 (73.4%) received oral metronidazole and 51 (26.6%) children received oral vancomycin. Baseline characteristics were similar between the 2 groups in the weighted cohort. Of 141 patients, 101 (71.7%) children receiving metronidazole had clinical improvement by day 5, whereas 44 of 51 (86.3%) cases resolved with vancomycin (odds ratio, 0.40; 95% confidence interval, 0.17–0.97; P = .04). The odds of CDI recurrence within 12 weeks were similar between the groups. Our study suggests that children with nonsevere CDI have earlier resolution of clinical symptoms when prescribed vancomycin compared with metronidazole. Large interventional studies are necessary to evaluate the reproducibility of our findings.